Objective:

To report the outcomes of two patients with resectable stage III EGFR-mutant NSCLC and high PD-L1 expression who achieved pathological complete response following neoadjuvant chemoimmunotherapy, highlighting the significance of PD-L1 levels in treatment efficacy.

Approach:

Key Findings:

• Both patients exhibited high PD-L1 expression (tumor proportion score 60%).
• Both achieved pathological complete response (pCR) after neoadjuvant chemoimmunotherapy.
• After 16 and 22 months of follow-up, both patients remain disease-free, with no signs of recurrence.

Interpretation:

These cases suggest that neoadjuvant chemoimmunotherapy may be effective for selected EGFR-mutant NSCLC patients with high PD-L1 expression, particularly after failure of targeted therapy, indicating a need for further exploration in clinical settings.

Limitations:

• Evidence is anecdotal and based on only two cases, which may not represent the broader population.
• Further validation through large-scale, prospective, biomarker-driven clinical trials is needed to confirm findings and address potential biases.

Conclusion:

Neoadjuvant chemoimmunotherapy may represent a promising strategy for specific EGFR-mutant NSCLC patients, but further research is essential to validate these findings and inform clinical practice.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.